RecruitingPhase 3NCT06493799
In Patients With Chronic Liver Diseases(Alcoholic Liver Disease and Non-Alcoholic Fatty Liver Disease), LAENNEC(Human Placenta Hydrolysate) is to Evaluate the Efficacy and Safety of Intravenous Drop
A Multicenter, Randomized, Open-label, Active-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous Drop of 'LAENNEC INJ. (Human Placenta Hydrolysate) Compared With Subcutaneous Injection in Patients With Chronic Liver Disease
Sponsor
Green Cross Wellbeing
Enrollment
226 participants
Start Date
Jul 1, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Control group : LAENNEC subcutaneous injection (4 ml) Experimental group : LAENNEC intravenous injection (10 ml)
Eligibility
Min Age: 19 YearsMax Age: 70 Years
Inclusion Criteria4
- At the time of screening, 19 or 70 years
- Those who have been diagnosed with alcoholic or non-alcoholic fatty liver disease
- Those who have increased ALT level (Increased ALT level : 60 IU/L ≤ ALT ≤ 200 IU/L)
- A person who can complete the signature agreement and comply with clinical trial requirements.
Exclusion Criteria32
- If you have the following disease
- Liver cancer or other malignant tumor within 5 years at screening point
- Esophageal varix bleeding, hepatic coma, ascites etc. related disease or Child-Pugh Score Class B,C patient within 1 year at screening point
- Organs or bone marrow transplant experience
- Billiary atresia, Genetic metabolic liver disease, Fulminant Hepatic failure, toxicity or Clinically diagnosed hepatitis, bleeding or Platelet disease patient
- Autoimmune hepatitis, Primary biliary cirrhosis, Sclerosing cholangitis, IgG4- associated cholangitis patient
- Bariatric Surgery within 24 weeks at screening point
- Uncontrolled diabetes mellitus (HBA1c \> 9.0%)
- Uncontrolled serious Cardiopulmonary disease
- Liver cancer or other malignant tumor within 5 years at screening point
- Those who have alcohol abuse within 5 years at screening point
- Hepatitis B, C virus (However, those who have been identified as HBV DNA undetectable or SVR after antiviral administration can participate)
- Systemic infection (including tuberculosis)
- If you are taking the following drug (Hepatotonics)
- However, it is possible to register after having a drug holiday
- Biphenyl dimethyl dicarboxylate (BDD), Silymarin(Milk thistle) : 14 days
- Ursodeoxycholic acid (UDCA) : 30 days
- Other Hepatotonics : 5 times half-life
- If you are taking the following drug or need to take drugs during the clinical trial period
- Antituberculous drug(Isoniazid, Rifampin etc.), antifungal agent and antibiotic
- Acetaminophen, NSAIDs(Excluding low-dose aspirin for preventive purposes)
- Lipid lowering agent(Niacin etc.) and Oral hypoglycemic agent(acarbose etc.) (Registered when administered during the clinical trial period with a certain dose without a change in dose currently being taken)
- Antiseric agent (ARB, Beta-blocker, CCB etc.) (Registered when administered during the clinical trial period with a certain dose without a change in dose currently being taken)
- Vitamin E (Purpose of treatment of more than 800 IU/day)
- Astrogens
- Systemic corticosteroids, Immunomodulator
- If you take more alcohol than the recommended amount (Man 40 g/day, Woman 20 g/day)
- Drug allergic symptoms (oscillation, heat, itching)
- Those who have received other clinical drugs within 4 weeks before selecting a test subject
- Those who cannot inject intravenous infusions (5% Dextrose Inj.)
- A person who does not perform appropriate contraception as a pregnant woman, a nursing or a woman of childbearing age (effective contraception method: Barrier methods using infertility surgery, uterine device, condom, killer)
- Those who judged that other testors were inappropriate as clinical trials
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGLAENNEC (Human Placenta Hydrolysate) IV
Intravenous Injection
DRUGLAENNEC (Human Placenta Hydrolysate) SC
Subcutaneous Injection
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06493799
Related Trials
Copper Supplementation in Cirrhosis
NCT074715421 location
FAST-IRM for HCC suRveillance in pAtients With High risK of Liver Cancer.
NCT050957141 location
Measuring Patient Reported Needs in Outpatient Liver Disease Management
NCT071918861 location
Endoscopic Ultrasound Shear Wave Elastography Study
NCT065928202 locations
hepatomiR cACLD Study
NCT064325821 location